AlzeCure

New anti-inflammatory data with NeuroRestore ACD856 at the Alzheimer's conference CTAD AlzeCure presentation at the Alzheimer's conference CTAD 2024 is now available in its entirety on the company's website. The presentation contains new preclinical data with the company's leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease, and being prepared for phase II. ”These new data suggest that ACD856 may play an anti-inflammatory and immunoregulatory role, in addition to the memory-enhancing and disease-modifying effects we have previously presented, and demonstrate its potential to slow neurodegeneration in Alzheimer's and other diseases characterized by neuroinflammation," said Dr. Cristina Parrado-Fernández, Senior Scientist at AlzeCure Pharma. “These new findings with NeuroRestore ACD856 have relevance not only for Alzheimer's, but also for other neurodegenerative diseases, such as Parkinson's and frontal lobe dementia. The results strengthen our commercial opportunities for ACD856, which we are now planning for phase II clinical studies in patients," said Martin Jönsson, CEO of AlzeCure Pharma. Read the press release: https://lnkd.in/dWj3SuZj The poster is available on AlzeCure's website https://lnkd.in/dUBj9yZ6 #alzecure #CTAD24 #ACD856 #alzheimers

CTAD 2024, Clinical Trials in Alzheimer’s Disease, has started. - We have so much to do in the fields of Alzheimer’s, so if we have seen tremendous development in the last five years with, for example improved diagnostics and anti-body treatments. This development has fueled the investments in the field, but the investment are still way to low, which is a shame, and bad health economically in a time where the societal cost are over one trillion US$, and its expected to triple in the coming thirty years. We at AlzeCure are proud to be here and present new data at the congress on our program NeuroRestore ACD856 which is presented by Cristina Parrado. Stay tuned on the data. #alzecure #ctad2024 #alzheimers #dementia #neurorestore

It has started … CTAD 2024 in Madrid #ctad2024 #alzecure

From our live event on October 23 The symposium, titled "ACD440 – A novel non-opioid analgesic", Dr. Karlsten provide an overview of the area of pain. https://lnkd.in/dqVhKgGk #alzecure #neuropathicpain #ACD440

From our live event on October 23 The symposium, titled "ACD440 – A novel non-opioid analgesic", Märta Segerdahl, CMO and project manager, gives an update on AlzeCure's clinical phase II candidate, ACD440, which is being developed as a new topical treatment for patients with chronic neuropathic pain. https://lnkd.in/d78abVuD #alzecure #neuropathicpain #ACD440

Nice that all those years of medicinal chemistry efforts paid off and led to the discovery of ACD137, a promising molecule with analgesic effects in models of neuropathic and nociceptive pain.

New positive data for the TrkA-NAM pain project against osteoarthritis AlzeCure has obtained new positive preclinical efficacy data supporting the continued development of the candidate drug ACD137 within the TrkA-NAM program. The new in vivo data, obtained in a rat model of osteoarthritis (OA) of the knee, show significant pain relief in both movement-induced and evoked pain as well as a significant anti-inflammatory effect. The analgesic effect of ACD137 is in line with the effect of the anti-NGF antibody Tanezumab, which have in several clinical trials demonstrated significant and robust pain relief, showing that ACD137 can reach the same efficacy as Tanezumab at the investigated doses. ACD137 treatment also significantly improved a number of cartilage and knee joint structural parameters suggesting a protective effect on knee-joint function in a model of osteoarthritis. Repeated administration of ACD137 for 18 days was well tolerated and there were no clinical symptoms or histopathological findings of rapidly progressing OA (RPOA), a problematic side effect observed for anti-NGF antibodies, including Tanezumab, nor were any effects seen on neuronal ganglia. "Interest in TrkA-NAM has increased further after Asahi Kasei recently started its phase 2b study with AK-1830 against knee osteoarthritis, which validates AlzeCure's project, where we have developed molecules that are even more potent and selective than AK-1830," said Martin Jönsson, CEO of AlzeCure Pharma. “The combination of potent analgesic effects and anti-inflammatory action could provide significant pain relief for patients, and also opens up other possible indications”. Read the press release https://lnkd.in/dRQGw-az #alzecure #TrkANAM #ACD137 #osteoarthritis #AK1830

I will attend CTAD Looking forward to attend CTAD Where we will present new data on NeuroRestore ACD856. NeuroRestore* is developed to improve memory and learning capabilities in patients with Alzheimer’s and other cognitive disorder, and is a Trk-PAM increasing BDNF and NGF signaling, and has also shown potential with regard to disease modifications. - Join me & let’s meet up at CTAD in Madrid. https://lnkd.in/dKtf_nK *) https://lnkd.in/e6BR563C #alzecure #partnering #CEO #CTAD24 #alzheimers #neurorestore

I will attend CTAD Looking forward to attend CTAD Where we will present new data on NeuroRestore ACD856. NeuroRestore* is developed to improve memory and learning capabilities in patients with Alzheimer’s and other cognitive disorder, and is a Trk-PAM increasing BDNF and NGF signaling, and has also shown potential with regard to disease modifications. - Join me & let’s meet up at CTAD in Madrid. https://lnkd.in/dKtf_nK *) https://lnkd.in/e6BR563C #alzecure #partnering #CEO #CTAD24 #alzheimers #neurorestore

Looking forward to attend Bioscience where Pontus will present AlzeCure and our ability to develope first in class molecules for several disease areas. - Come and join. #alzecure #neuroscience #bioscience2024